Rezvoglar Injection, Solution
NDC Package 0002-8980-05

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Rezvoglar (insulin glargine-aglr) injection is rEZVOGLAR™ is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. This formulation utilizes a injection, solution delivery system. Marketed by Eli Lilly And Company, this product is identified by NDC 0002-8980 and is authorized under FDA application BLA761215.

Identification & Billing

NDC Package Code
0002-8980-05
Package Description
5 SYRINGE in 1 CARTON / 3 mL in 1 SYRINGE (0002-8980-01)
Product Code
0002-8980
11-Digit Billing Format
00002898005
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 2589008 - insulin glargine-aglr 300 UNT in 3 ML Pen Injector
  • RxCUI: 2589008 - 3 ML insulin glargine-aglr 100 UNT/ML Pen Injector
  • RxCUI: 2589008 - insulin glargine-aglr 300 UNT per 3 ML Pen Injector
  • RxCUI: 2589014 - REZVOGLAR (insulin glargine-aglr) 100 UNT/ML in 3 ML Pen Injector
  • RxCUI: 2589014 - 3 ML insulin glargine-aglr 100 UNT/ML Pen Injector [Rezvoglar]

Clinical Specifications

Proprietary Name
Rezvoglar Kwikpen
Non-Proprietary Name
Insulin Glargine-aglr
Substance Name
Insulin Glargine
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
INSULIN GLARGINE 100 [iU]/mL
Pharmacologic Class
Usage Information
REZVOGLAR™ is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Limitations of UseREZVOGLAR is not recommended for the treatment of diabetic ketoacidosis.

Regulatory & Marketing

Labeler Name
Eli Lilly And Company
Product Type
Human Prescription Drug
FDA Application #
BLA761215
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
12-17-2021
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0002-8980-05 identifies a specific commercial package of 5 syringe in 1 carton / 3 ml in 1 syringe (0002-8980-01) of Rezvoglar Kwikpen, a human prescription drug labeled by Eli Lilly And Company. This injection, solution is formulated for subcutaneous use and contains insulin glargine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eli Lilly And Company on December 17, 2021. The current certification is valid through December 31, 2026.

How is this Eli Lilly And Company product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00002898005. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0002-8980-05
11-Digit CMS (5-4-2)
00002-8980-05

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.